AU2016309948B2 - Connexin 45 inhibition for therapy - Google Patents

Connexin 45 inhibition for therapy Download PDF

Info

Publication number
AU2016309948B2
AU2016309948B2 AU2016309948A AU2016309948A AU2016309948B2 AU 2016309948 B2 AU2016309948 B2 AU 2016309948B2 AU 2016309948 A AU2016309948 A AU 2016309948A AU 2016309948 A AU2016309948 A AU 2016309948A AU 2016309948 B2 AU2016309948 B2 AU 2016309948B2
Authority
AU
Australia
Prior art keywords
sequence
inhibitor
vector
ventricular
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016309948A
Other languages
English (en)
Other versions
AU2016309948A1 (en
Inventor
Peter FAHMY
Eddy KIZANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Western Sydney Local Health District
Original Assignee
University of Sydney
Western Sydney Local Health District
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903282A external-priority patent/AU2015903282A0/en
Application filed by University of Sydney, Western Sydney Local Health District filed Critical University of Sydney
Publication of AU2016309948A1 publication Critical patent/AU2016309948A1/en
Application granted granted Critical
Publication of AU2016309948B2 publication Critical patent/AU2016309948B2/en
Priority to AU2021215254A priority Critical patent/AU2021215254A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016309948A 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy Active AU2016309948B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021215254A AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903282A AU2015903282A0 (en) 2015-08-14 Connexin 45 Inhibition for Therapy
AU2015903282 2015-08-14
PCT/AU2016/050740 WO2017027910A1 (en) 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021215254A Division AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Publications (2)

Publication Number Publication Date
AU2016309948A1 AU2016309948A1 (en) 2018-03-08
AU2016309948B2 true AU2016309948B2 (en) 2021-05-20

Family

ID=58050389

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016309948A Active AU2016309948B2 (en) 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy
AU2021215254A Abandoned AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021215254A Abandoned AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Country Status (6)

Country Link
US (1) US10709726B2 (https=)
EP (2) EP3334746B1 (https=)
JP (2) JP2018529759A (https=)
AU (2) AU2016309948B2 (https=)
CA (1) CA3033909A1 (https=)
WO (1) WO2017027910A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200061210A1 (en) * 2018-08-27 2020-02-27 BioViva USA, Inc. Novel method for gene therapy using intranasal administration of genetically modified viral vectors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053600A2 (en) * 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2012065143A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA962806A (en) 1970-06-04 1975-02-18 Ontario Research Foundation Surgical prosthetic device
US4101984A (en) 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
US4281669A (en) 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
IT1196836B (it) 1986-12-12 1988-11-25 Sorin Biomedica Spa Protesi in materiale polimerico con rivestimento di carbonio biocompatibile
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5163958A (en) 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5236457A (en) 1992-02-27 1993-08-17 Zimmer, Inc. Method of making an implant having a metallic porous surface
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE19855421C2 (de) 1998-11-02 2001-09-20 Alcove Surfaces Gmbh Implantat
KR20030045847A (ko) 2000-10-31 2003-06-11 쿡 인코포레이티드 코팅된 이식형 의료 장치
DK1521603T3 (da) 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
CA2503625A1 (en) 2002-11-13 2004-05-27 Setagon, Inc. Medical devices having porous layers and methods for making same
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US20180099029A9 (en) 2010-04-15 2018-04-12 Mount Sinai School Of Medicine Serca2 therapeutic compositions and methods of use
EP2655621B1 (en) * 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
WO2015191795A1 (en) 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053600A2 (en) * 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2012065143A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas

Also Published As

Publication number Publication date
US10709726B2 (en) 2020-07-14
JP7668686B2 (ja) 2025-04-25
EP3334746A1 (en) 2018-06-20
EP3334746B1 (en) 2021-11-24
JP2018529759A (ja) 2018-10-11
AU2016309948A1 (en) 2018-03-08
EP3334746A4 (en) 2019-04-24
CA3033909A1 (en) 2017-02-23
US20190030063A1 (en) 2019-01-31
WO2017027910A1 (en) 2017-02-23
AU2021215254A1 (en) 2021-09-02
EP4043074A1 (en) 2022-08-17
JP2021176848A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
AU2018311504B2 (en) Cellular models of and therapies for ocular diseases
Zhang et al. Long non-coding RNA CCRR controls cardiac conduction via regulating intercellular coupling
Galbiati et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism
KR20200057766A (ko) 페닐케톤뇨증을 치료하기 위한 프로모터 및 인핸서 조합을 포함하는 벡터
US20220023384A1 (en) Mybpc3 polypeptides and uses thereof
CN116171325A (zh) 用于eEF1A2的基因疗法载体及其用途
US20200308582A1 (en) Kcnk3-based gene therapy of cardiac arrhythmia
JP2022543589A (ja) Ｋｌｆ誘導心筋再生
CN116887868A (zh) 达农病的治疗
JP2007516230A (ja) 心臓組織の変性を治療及び予防するための組成物及び方法並びにその用途
EP3285813B1 (en) Smad7 gene delivery as a therapeutic
JP7668686B2 (ja) 治療用コネキシン４５阻害剤
Pratt et al. Evaluating the feasibility of gene replacement strategies to treat MTRFR deficiency
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
US20230313182A1 (en) Preparation method for diabetes early warning and/or diagnostic reagent kit based on hsa-mir-320a, medicament for preventing diabetes, screening method for medicament, and preparation method therefor
CN120860261B (zh) Angulin-1基因和/或Angulin-1蛋白在制备抗衰老及治疗衰老相关疾病的产品中的应用
CN118697878B (zh) Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用
US20220349876A1 (en) Use of dkk1 inhibitor in prevention and/or treatment of tumor cachexia and diseases associated with diabetes
WO2025030125A1 (en) Applications of cmya5 minigenes
Sacal Inherited Arrhythmogenic Cardiac Diseases and the Kir2. 1-NaV1. 5 Channelosome
WO2025060840A1 (zh) Bcor和Zc3h12a在预防和治疗慢性感染中的用途
CN121588221A (zh) 一种预防和治疗黄热病毒感染的药物和方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)